COVID-19血液透析患者死亡率相关因素

IF 0.2 Q4 UROLOGY & NEPHROLOGY Journal of Renal Injury Prevention Pub Date : 2022-02-01 DOI:10.34172/jrip.2022.32005
G. Yilmaz, O. Timur
{"title":"COVID-19血液透析患者死亡率相关因素","authors":"G. Yilmaz, O. Timur","doi":"10.34172/jrip.2022.32005","DOIUrl":null,"url":null,"abstract":"Introduction: The mortality rate in COVID-19 patients is about 2%, however advanced age, male gender, comorbid diseases increase the risk of mortality. Patients with end-stage renal disease (ESRD) and hemodialysis (HD) treatment are more susceptible to infection due to both existing comorbid diseases and immune suppression caused by uremia. Objectives: This study aims to show the potential of easily obtainable, inexpensive and reproducible markers in predicting mortality in HD patients at the time of diagnosis. Patients and Methods: In this study, we examined the relationship between; neutrophil to lymphocyte ratio (NLR), mean platelet volume (MPV) and C-reactive protein (CRP)/albumin values at the time of hospital admission with mortality in 75 HD patients diagnosed with COVID-19. All analyses were conducted using IBM SPSS Statistics 21.0 and MS-Excel 2010 software. Results: A total of 75 HD patients diagnosed with COVID-19 were included in the study. Out of these, at least 19 (25.3%) patients received hydroxychloroquine, 68 (90.6%) patients favipiravir, two (2.6%) patients tocilizumab and two patients (2.6%) immune plasma therapy. Among these patients, sixteen patients (21.3%) needed invasive mechanic ventilation, eight patients (10.6%) needed high flow oxygen and seven patients (9.3%) needed non-invasive mechanic ventilation and 17 of 75 patients (23%) died. A total of 14 of the 17 non-survivors were intubated. In comparison between survivors and non-survivors in our study; NLR, MPV, CRP, CRP/albumin and phosphorus values were significantly higher in the non-survivors group. Conclusion: According to this study, NLR, MPV and CRP/albumin values are associated with mortality in HD patients affected with COVID-19.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Factors related to mortality in hemodialysis patients with COVID-19\",\"authors\":\"G. Yilmaz, O. Timur\",\"doi\":\"10.34172/jrip.2022.32005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: The mortality rate in COVID-19 patients is about 2%, however advanced age, male gender, comorbid diseases increase the risk of mortality. Patients with end-stage renal disease (ESRD) and hemodialysis (HD) treatment are more susceptible to infection due to both existing comorbid diseases and immune suppression caused by uremia. Objectives: This study aims to show the potential of easily obtainable, inexpensive and reproducible markers in predicting mortality in HD patients at the time of diagnosis. Patients and Methods: In this study, we examined the relationship between; neutrophil to lymphocyte ratio (NLR), mean platelet volume (MPV) and C-reactive protein (CRP)/albumin values at the time of hospital admission with mortality in 75 HD patients diagnosed with COVID-19. All analyses were conducted using IBM SPSS Statistics 21.0 and MS-Excel 2010 software. Results: A total of 75 HD patients diagnosed with COVID-19 were included in the study. Out of these, at least 19 (25.3%) patients received hydroxychloroquine, 68 (90.6%) patients favipiravir, two (2.6%) patients tocilizumab and two patients (2.6%) immune plasma therapy. Among these patients, sixteen patients (21.3%) needed invasive mechanic ventilation, eight patients (10.6%) needed high flow oxygen and seven patients (9.3%) needed non-invasive mechanic ventilation and 17 of 75 patients (23%) died. A total of 14 of the 17 non-survivors were intubated. In comparison between survivors and non-survivors in our study; NLR, MPV, CRP, CRP/albumin and phosphorus values were significantly higher in the non-survivors group. Conclusion: According to this study, NLR, MPV and CRP/albumin values are associated with mortality in HD patients affected with COVID-19.\",\"PeriodicalId\":16950,\"journal\":{\"name\":\"Journal of Renal Injury Prevention\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2022-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Renal Injury Prevention\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34172/jrip.2022.32005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Renal Injury Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jrip.2022.32005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言:COVID-19患者的死亡率约为2%,但高龄、男性、合并症会增加死亡风险。终末期肾病(ESRD)和血液透析(HD)治疗的患者由于存在合并症和尿毒症引起的免疫抑制,更容易感染。目的:本研究旨在展示易于获得、廉价且可重复的标记物在HD患者诊断时预测死亡率的潜力。患者和方法:在本研究中,我们研究了;75例诊断为COVID-19的HD患者入院时中性粒细胞与淋巴细胞比值(NLR)、平均血小板体积(MPV)和c反应蛋白(CRP)/白蛋白值与死亡率的关系采用IBM SPSS Statistics 21.0和MS-Excel 2010软件进行分析。结果:共纳入75例诊断为COVID-19的HD患者。其中,至少19例(25.3%)患者接受羟氯喹治疗,68例(90.6%)患者接受法匹拉韦治疗,2例(2.6%)患者接受托珠单抗治疗,2例(2.6%)患者接受免疫血浆治疗。其中有创机械通气16例(21.3%),高流量供氧8例(10.6%),无创机械通气7例(9.3%),死亡17例(23%)。17例未存活患者中有14例接受了插管治疗。在我们的研究中,幸存者和非幸存者的比较;非幸存者组NLR、MPV、CRP、CRP/白蛋白和磷值均显著升高。结论:根据本研究,NLR、MPV和CRP/白蛋白值与COVID-19合并HD患者的死亡率相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Factors related to mortality in hemodialysis patients with COVID-19
Introduction: The mortality rate in COVID-19 patients is about 2%, however advanced age, male gender, comorbid diseases increase the risk of mortality. Patients with end-stage renal disease (ESRD) and hemodialysis (HD) treatment are more susceptible to infection due to both existing comorbid diseases and immune suppression caused by uremia. Objectives: This study aims to show the potential of easily obtainable, inexpensive and reproducible markers in predicting mortality in HD patients at the time of diagnosis. Patients and Methods: In this study, we examined the relationship between; neutrophil to lymphocyte ratio (NLR), mean platelet volume (MPV) and C-reactive protein (CRP)/albumin values at the time of hospital admission with mortality in 75 HD patients diagnosed with COVID-19. All analyses were conducted using IBM SPSS Statistics 21.0 and MS-Excel 2010 software. Results: A total of 75 HD patients diagnosed with COVID-19 were included in the study. Out of these, at least 19 (25.3%) patients received hydroxychloroquine, 68 (90.6%) patients favipiravir, two (2.6%) patients tocilizumab and two patients (2.6%) immune plasma therapy. Among these patients, sixteen patients (21.3%) needed invasive mechanic ventilation, eight patients (10.6%) needed high flow oxygen and seven patients (9.3%) needed non-invasive mechanic ventilation and 17 of 75 patients (23%) died. A total of 14 of the 17 non-survivors were intubated. In comparison between survivors and non-survivors in our study; NLR, MPV, CRP, CRP/albumin and phosphorus values were significantly higher in the non-survivors group. Conclusion: According to this study, NLR, MPV and CRP/albumin values are associated with mortality in HD patients affected with COVID-19.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Renal Injury Prevention
Journal of Renal Injury Prevention UROLOGY & NEPHROLOGY-
CiteScore
1.60
自引率
0.00%
发文量
36
期刊介绍: The Journal of Renal Injury Prevention (JRIP) is a quarterly peer-reviewed international journal devoted to the promotion of early diagnosis and prevention of renal diseases. It publishes in March, June, September and December of each year. It has pursued this aim through publishing editorials, original research articles, reviews, mini-reviews, commentaries, letters to the editor, hypothesis, case reports, epidemiology and prevention, news and views and renal biopsy teaching point. In this journal, particular emphasis is given to research, both experimental and clinical, aimed at protection/prevention of renal failure and modalities in the treatment of diabetic nephropathy. A further aim of this journal is to emphasize and strengthen the link between renal pathologists/nephropathologists and nephrologists. In addition, JRIP welcomes basic biomedical as well as pharmaceutical scientific research applied to clinical nephrology. Futuristic conceptual hypothesis that integrate various fields of acute kidney injury and renal tubular cell protection are encouraged to be submitted.
期刊最新文献
Relationship between contrast-induced nephropathy and blood methemoglobin levels in acute coronary syndrome patients Predictors of glomerular IgA immunostaining patterns and disease progression in IgA nephropathy patients; a 13-year study of clinical and morphological features of renal biopsies A comparative study of true and pseudo-peroxidase and their relative biomarkers between male and female patients with chronic kidney disease Association between cadmium exposure and risk of chronic kidney disease; a systematic review and meta-analysis Treatment outcomes of multiple myeloma in patients requiring renal replacement therapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1